Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.9000
+0.1752 (24.17%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Sutro Biopharma Stock Forecast
STRO's stock price has decreased by -76.13% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 6.83, with a low estimate of 1.00 and a high estimate of 15. The average target predicts an increase of 658.89% from the current stock price of 0.90.
Analyst Consensus: Buy
* Price targets were last updated on Mar 17, 2025.
Analyst Ratings
The average analyst rating for Sutro Biopharma stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $12 → $2 | Strong Buy → Hold | Downgrades | $12 → $2 | +122.22% | Mar 17, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +122.22% | Mar 14, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $11 → $1 | Strong Buy → Sell | Downgrades | $11 → $1 | +11.11% | Mar 14, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +1,788.89% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
48.09M
from 62.04M
Decreased by -22.49%
Revenue Next Year
48.71M
from 48.09M
Increased by 1.29%
EPS This Year
-2.24
from -2.96
EPS Next Year
-1.39
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.4M | 96.8M | 169.5M | ||
| Avg | 48.1M | 48.7M | 60.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.0% | 101.4% | 248.0% | ||
| Avg | -22.5% | 1.3% | 25.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.76 | -0.21 | -0.01 | ||
| Avg | -2.24 | -1.39 | -1.31 | ||
| Low | -2.69 | -3.19 | -2.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.